Twist Bioscience (TWST) to Release Earnings on Monday

Twist Bioscience (NASDAQ:TWST) will release its earnings data before the market opens on Monday, November 18th. Analysts expect Twist Bioscience to post earnings of ($0.73) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Twist Bioscience Trading Down 5.3 %

NASDAQ TWST opened at $36.89 on Friday. Twist Bioscience has a 1-year low of $18.80 and a 1-year high of $60.90. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -9.66 and a beta of 1.78. The company has a 50 day moving average of $43.90 and a 200-day moving average of $45.91.

Wall Street Analyst Weigh In

TWST has been the subject of a number of recent analyst reports. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird upped their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Insiders Place Their Bets

In other news, insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the sale, the insider now owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This represents a 1.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Patrick John Finn sold 10,340 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the sale, the chief operating officer now owns 221,061 shares of the company’s stock, valued at $10,610,928. This represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 in the last quarter. Corporate insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.